A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective

A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective

Abstract Background In 2023, the US CDC recommended 20-valent pneumococcal conjugate vaccine (PCV20) or 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65-years and older and those aged 19–64 years old with chron...

Full description

Saved in:
Bibliographic Details
Main Authors: Nirma Khatri Vadlamudi, Chyongchiou J. Lin, Angela R. Wateska, Richard K. Zimmerman, Kenneth J. Smith
Format: Article
Language:English
Published: BMC 2025-06-01
Series:BMC Public Health
Subjects:
Pneumococcal
Budget impact analyses
Vaccine
US
Adults
Online Access:https://doi.org/10.1186/s12889-025-22827-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12889-025-22827-9

Similar Items